CCCC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CCCC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
C4 Therapeutics has the Growth Rank of 2.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, C4 Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, C4 Therapeutics's Growth Rank distribution charts can be found below:
* The bar in red indicates where C4 Therapeutics's Growth Rank falls into.
Thank you for viewing the detailed overview of C4 Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott N Boyle | officer: Chief Business Officer | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Mark Mossler | officer: Chief Accounting Officer | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472 |
Kendra Adams | officer: Chief Financial Officer | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472 |
Leonard Reyno | officer: Chief Medical Officer | 607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004 |
Utpal Koppikar | director | C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080 |
Donna Roy Grogan | director | 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633 |
Laura Bessen | director | 4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121 |
Andrew Hirsch | director, officer: See Remarks | C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139 |
Kelly Schick | officer: Chief People Officer | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Malcolm Salter | director | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Adam Crystal | officer: Chief Medical Officer | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Elena Prokupets | director | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Jolie Siegel | officer: Chief Legal Officer | C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139 |
Stewart Fisher | officer: Chief Scientific Officer | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
Lauren White | officer: Chief Financial Officer | C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472 |
From GuruFocus
By Marketwired • 11-06-2024
By Marketwired • 10-15-2024
By Marketwired • 10-31-2024
By Marketwired • 10-28-2024
By Marketwired • 09-08-2024
By GuruFocus News • 11-15-2024
By Marketwired • 02-24-2025
By GlobeNewswire • 12-08-2024
By GuruFocus News • 02-27-2025
By Marketwired • 08-01-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.